About: A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19)
Creator	Javad, Mohammad Amir, & Ghafoori, Majid Hosseinzadeh, Hossein Mohammadpour, Hooshang Nayeri, Dehghan Rameshrad, Maryam
Source	Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the reason for this ongoing pandemic infection diseases termed coronavirus disease 2019 (COVID-19) that has emerged since early December 2019 in Wuhan City, Hubei Province, China. In this century, it is the worst threat to international health and the economy. After 4 months of COVID-19 outbreak, there is no certain and approved medicine against it. In this public health emergency, it makes sense to investigate the possible effects of old drugs and find drug repositioning that is efficient, economical, and riskless process. Old drugs that may be effective are from different pharmacological categories, antimalarials, anthelmintics, anti-protozoal, anti-HIVs, anti-influenza, anti-hepacivirus, antineoplastics, neutralizing antibodies, immunoglobulins, and interferons. In vitro, in vivo, or preliminary trials of these drugs in the treatment of COVID-19 have been encouraging, leading to new research projects and trials to find the best drug/s. In this review, we discuss the possible mechanisms of these drugs against COVID-19. Also, it should be mentioned that in this manuscript, we discuss preliminary rationales; however, clinical trial evidence is needed to prove them. COVID-19 therapy must be based on expert clinical experience and published literature and guidelines from major health organizations. Moreover, herein, we describe current evidence that may be changed in the future.
has issue date	2020-05-19(xsd:dateTime)
bibo:doi	10.1007/s00210-020-01901-6
bibo:pmid	32430617
has license	no-cc
sha1sum (hex)	9a2eedca015251d76f210dd5b945539e9946f36c
schema:url	https://doi.org/10.1007/s00210-020-01901-6
resource representing a document's title	A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19)
has PubMed Central identifier	PMC7235439
has PubMed identifier	32430617
schema:publication	Naunyn Schmiedebergs Arch Pharmacol
resource representing a document's body	covid:9a2eedca015251d76f210dd5b945539e9946f36c#body_text
is schema:about of	named entity 'needed' named entity 'literature' named entity 'PRELIMINARY' named entity 'experience' named entity 'infection diseases' named entity 'COVID-19' named entity 'COVID19' named entity 'PARP1' named entity 'IL-6' named entity 'cell-mediated immunity' named entity 'PARP1' named entity 'chloroquine' named entity 'virus' named entity 'COVID' named entity 'Japan' named entity 'MERS' named entity 'type 1 interferon' named entity 'cell cycle' named entity 'Corticosteroid therapy' named entity 'metabolized' named entity 'antineoplastic drugs' named entity 'bacterial infection' named entity 'nausea' named entity 'nausea' named entity 'protein' named entity 'spike protein' named entity 'chloroquine' named entity 'ADP-ribose' named entity 'vomiting' named entity 'spike protein' named entity 'respiratory tract' named entity 'SARS-CoV' named entity 'RNA polymerase' named entity 'Moxifloxacin' named entity 'lopinavir/ritonavir' named entity 'viral core' named entity 'neutralizing antibodies' named entity 'influenza' named entity 'Edema' named entity 'prodrug' named entity 'septic shock' named entity 'dimer' named entity 'ADP-ribose' named entity 'chikungunya' named entity 'passive immunity' named entity 'NADPH oxidase' named entity 'synergic' named entity 'catalytic site' named entity 'COVID' named entity 'clathrin-mediated endocytosis' named entity 'COVID' named entity 'macrophage inflammatory protein' named entity 'Tanne' named entity 'clinical features' named entity 'arrhythmia' named entity 'coronavirus' named entity 'viral replication cycle' named entity 'hematological' named entity 'community-acquired pneumonia' named entity 'COVID' named entity 'coronavirus' named entity 'lactate dehydrogenase' named entity 'viremia' named entity 'COVID' named entity 'viral shedding' named entity 'granulocyte-colony stimulating factor' named entity 'IL-6' named entity 'virus' named entity 'cyclosporine' named entity 'IL-1' named entity 'skin rash' named entity 'proinflammatory cytokines' named entity 'Remdesivir' named entity 'HCV' named entity 'peramivir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software